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The AMPK 2 Subunit Is Required for Energy Homeostasis during
Metabolic Stress
Biplab Dasgupta,a Jeong Sun Ju,b Yo Sasaki,e Xiaona Liu,a Su-Ryun Jung,c Kazuhiko Higashida,c Diana Lindquist,d and
Jeffrey Milbrandte
Department of Pediatrics, Division of Hematology and Oncology,a and Imaging Research Center, Department of Radiology,d Cincinnati Children’s Hospital Medical
Center, Cincinnati, Ohio, USA, and Departments of Neurologyb and Internal Medicinec and Department of Genetics and HOPE Center for Neurological Disorders,e
Washington University School of Medicine, St. Louis, Missouri, USA
AMP activated protein kinase (AMPK) plays a key role in the regulatory network responsible for maintaining systemic energy
homeostasis during exercise or nutrient deprivation. To understand the function of the regulatory 2 subunit of AMPK in sys-
temic energy metabolism, we characterized 2 subunit-deficient mice. Using these mutant mice, we demonstrated that the 2
subunit plays an important role in regulating glucose, glycogen, and lipid metabolism during metabolic stress. The 2 mutant
animals failed to maintain euglycemia andmuscle ATP levels during fasting. In addition, 2-deficient animals showed classic
symptoms of metabolic syndrome, including hyperglycemia, glucose intolerance, and insulin resistance whenmaintained on a
high-fat diet (HFD), and were unable to maintain muscle ATP levels during exercise. Cell surface-associated glucose transporter
levels were reduced in skeletal muscle from 2 mutant animals on an HFD. In addition, they displayed poor exercise perfor-
mance and impaired muscle glycogenmetabolism. These mutant mice had decreased activation of AMPK and deficits in PGC1-
mediated transcription in skeletal muscle. Our results highlight specific roles of AMPK complexes containing the 2 subunit and
suggest the potential utility of AMPK isoform-specific pharmacological modulators for treatment of metabolic, cardiac, and
neurological disorders.
AMP activated protein kinase (AMPK) plays a crucial role inmaintaining systemic energy homeostasis through its coordi-
nated actions on the central nervous system and peripheral tissues
(54). Loss of AMPK function causes metabolic abnormalities in
mice and defects in development and growth, cell polarity, and
structure in plants,Drosophila, and rodents (1, 10, 33). Moreover,
AMPK is necessary for caloric restriction-mediated longevity in
Caenorhabditis elegans (19). AMPK is an intracellular energy sen-
sor. When intracellular levels of ATP decrease, a corresponding
increase inAMP leads to activation ofAMPK, a step that is vital for
restoring intracellular energy balance via AMPK-dependent inhi-
bition of energy-consuming biosynthetic processes and concom-
itant activation of pathways that increase ATP production.
AMPK is a multisubstrate, heterotrimeric serine/threonine ki-
nase consisting of one , one , and one  subunit. The mamma-
lian genome encodes two , two , and three  subunits. The N
terminus of the  subunit contains the catalytic domain as well as
a phosphorylation site for upstream kinases that regulate its activ-
ity (9). The  subunits are nucleotide binding regulatory subunits
that bind AMP. The conserved C terminus of the  subunit inter-
acts with both the  and  subunits and plays an obligatory role in
AMPK complex formation (10, 46). In addition,  subunits con-
tain a conserved carbohydrate-binding domain that allows AMPK
to function as a glycogen sensor (37, 42).
While AMPK is present in all tissues, the individual AMPK
subunits display considerable variation in tissue-specific expres-
sion, subunit association, and subcellular localization. Earlier
studies demonstrated that the 2 catalytic subunit associates ex-
clusively with 1 in slow-twitch (type I) soleus muscle fibers,
whereas in fast-twitch (type II) extensor digitorum longus (EDL)
muscle fibers, 2 associates with both 1 and 2 subunits (7, 49).
Furthermore, in skeletal muscle, the 2, but not the 1, subunit
translocates to the nucleus in response to exercise (38). The 1
subunit is highly expressed in brain and liver, whereas 2 is most
highly expressed in skeletal muscle (48). In addition, 1 is pre-
dominantly located in the nucleus in neurons (50) and neural
stem cells, whereas 2 is predominantly cytoplasmic (10). The
subcellular localization of  subunits is undoubtedly important
for AMPK function, as studies in yeasts showed that they direct
localization of the catalytic  subunit and thus regulate substrate
selection (45).
To study the functions of the 2 subunit, we generated and
characterized 2-deficient mice. Here, we report that the 2-de-
ficient mice are overtly normal but display severe deficiencies in
energy homeostasis when subjected to metabolic stress. These
studies illustrate an important role for the2 subunit in regulating
AMPK function during times of increased energy demands.
MATERIALS AND METHODS
Generation of AMPK 2-deficient mice. Embryonic stem (ES) cells
(clone AL0483; 129/Ola) containing an AMPK2 gene trap allele were
obtained from Bay Genomics, San Francisco, CA. Briefly, AMPK2 gene
trap ES cells were microinjected into blastocysts derived from superovu-
lated pregnant mice, and these blastocysts were injected into pseudopreg-
nant C57BL/6 females. Chimeric males (129/Ola mixed background)
were mated with C57BL/6 females, and germ line transmission was con-
firmed by PCR genotyping of tail DNA. All procedures were carried out in
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the Washington University animal care facility. The insertion site of the
gene trap within the2 locus was identified using a PCR ladder approach.
Ten forward primers were designed 250 bp apart within exon 2 and the
following intron, where the -geo trap was putatively inserted. The re-
verse primer was designed from the En2 sequence located in the gene trap
N terminus (primer c in Fig. 1C). PCR fragments were obtained and
sequenced to identify the site of insertion. Primer a, which was closest to
the insertion site, was used for subsequent PCR genotyping reactions (Fig.
1C). The wild-type (WT) 2 fragment was detected using primer a and a
reverse primer (primer b in Fig. 1C) corresponding to 2 intronic se-
quences located 300 nucleotides (nt) downstream of the gene trap 5=
junction. Animals were backcrossed for at least 10 generations with
C57BL/6 mice to achieve a pure C57BL/6 background.
Immunoprecipitation, subcellular fractionation, and Western blot
analysis. Freshly dissected tissues were lysed with MAPK lysis buffer (20
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM -glycerophos-
phate, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 1 mM dithiothreitol [DTT], and protease inhibitor cocktail).
Membranes were prepared from skeletal muscle by following an estab-
lished protocol (44). AMPK was immunoprecipitated with AMPK1/2
antibody (Cell Signaling Technology, Beverly, MA). The primary anti-
body was incubated with 100g of protein lysate at 4°C for 16 h, followed
by incubation with 10 l of protein G beads for 1 h at 4°C. The immune
complexes were then collected by centrifugation. The immunoprecipi-
tated proteins were electrophoresed through an SDS-polyacrylamide gel
and analyzed by standard immunoblot analysis. Immunoblot analysis was
carried out with the following primary antibodies: AMPK1/2 C terminus,
AMPK1/2, phospho-AMPK1/2Thr172, ACC, phospho-ACCSer79, phos-
phorylated RaptorSer792 (pRaptorSer792), pULK1Ser555, pS6Ser235/236,
p4EBP1Thr70, actin, and tubulin (all from Cell Signaling Technology),
pFOXO3 Ser413, pFOXO3Ser588 (kind gift from Anne Brunet, Stanford Uni-
versity), and Glut4 (rabbit polyclonal, a kind gift from Paul Hruz, Washing-
tonUniversity, St. Louis,MO).Detectionwas performedusing anti-rabbit or
anti-mouse horseradishperoxidase (HRP)-linked secondary antibodies (Cell
Signaling Technology), followed by chemiluminescence (Millipore, Billerica,
MA).Densitometric scanswere performedusingGel-Pro-Analyzer software.
SAMS peptide assay. SAMS peptide assays to monitor AMPK activity
were performed as described previously, with some modifications (13,
53). Briefly, tissues were homogenized with a motorized tissue homoge-
FIG 1 Skeletal muscle predominantly expresses the AMPK 2 subunit. (A) Immunoblot analysis using 1/2 C-terminus-specific antibody detects expression
of 1 and 2 inWT tissues. (B) Immunoblot analysis of type I (soleus and quadriceps), type II (tibialis), andmixed (gastrocnemius) skeletal muscle and cardiac
muscle using 1/2 C-terminus-specific antibody. (C) Numbers 1 to 7 are exons of the 2 gene; a, b, and c are genotyping primers for wild-type andmutant 2
alleles. SA, splice acceptor; -Geo, -galactosidase-neomycin resistance cassette; PA, polyadenylation signal. (D) Genotyping PCR of tail DNA from 2 mutant
(/), WT (/), and heterozygote (/) animals. (E) Immunoblot analysis using 1/2 C-terminus-specific antibody showing the absence of 2 subunit
expression in all organs of 2 mutant mice.
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nizer for 20 to 30 s in 500l of ice-cold buffer (225mMmannitol, 75mM
sucrose, 10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 5 mM sodium pyro-
phosphate, 50 mM NaF, 1 mM dithiothreitol, 1.5 mM PMSF, and pro-
tease inhibitor cocktail). The homogenate was centrifuged for 1 min at
15,000 g, and the supernatant was stored in aliquots at80°C for later
determination of protein concentration and AMPK activity. AMPK
holoenzyme was immunoprecipitated using AMPK1/2 antibody and
protein G-agarose from 200 g of protein lysate; the beads were washed
twice with kinase buffer (20 mM Tris-HCl [pH 7.5], 7.5 mM MgCl2, 0.5
mMEGTA, 25mM-glycerophosphate, 0.5mMsodiumvanadate, 1mM
PMSF, and protease inhibitor cocktail) and used in the kinase reaction (25
l of immunoprecipitated beads). The kinase reaction mixture contain-
ing immunoprecipitated AMPK, 100 M SAMS peptide substrate, 200
MAMP, and 1l (2Ci) of [32P]ATPwas incubated at 30°C for 20min
with gentle agitation. The reactionwas centrifuged to pellet the beads, and
20 l of supernatant was spotted on Whatman P81 paper. The filter pa-
pers were washed thrice with 1% phosphoric acid and once with acetone
and air dried, and radioactivity was counted using a scintillation counter.
Measurement of glucose, insulin, serum cholesterol, lipids, and gly-
cogen.Glucose levels were determined using an Accu-Chek II glucometer
(Roche Diagnostics) with blood collected from the tail vein. Insulin levels
were determined by an enzyme-linked immunosorbent assay (ELISA) kit
(Singulex insulin assay) with mouse insulin standards (ALPCO) at the
Immunoassay Core of the Core Laboratory for Clinical Studies at Wash-
ington University School of Medicine. Total triglycerides and total cho-
lesterol were measured using Infinity cholesterol and triglyceride kits
(Fisher Scientific), and free fatty acids were determined by a two-step
method using reagents from WAKO Chemicals according to the manu-
facturer’s instructions. These measurements were done in the Clinical
Nutrition Research Unit (CNRU) at Washington University School of
Medicine. Muscle samples were stored at 80°C until analyzed. Muscle
glycogen was analyzed with a glycogen assay kit (BioVision) according to
themanufacturer’s instructions. Briefly,25mg ofmuscle was ground in
0.3 M perchloric acid at 4°C. Muscle glycogen content was measured by a
colorimetric assay using an ELX-800 universal plate reader (Bio-Tek,
Winooski, VT) set at an absorbance reading of 570 nm.
Glucose tolerance and insulin sensitivity test. For glucose tolerance
tests (GTT), mice were injected with dextrose (2 g/kg body weight) and
blood glucose levels were measured at 0, 30, 60, and 120 min after injec-
tion. Plasma was also collected at 0, 15, and 30min after glucose injection
and submitted to theWashingtonUniversity RIA Core Facility for insulin
measurements. For insulin tolerance tests (ITT), mice were fasted for 4 h;
human insulin (0.75 U/kg body weight; 100 U/ml; Lilly) was injected
intraperitoneally and blood glucose levels were measured at 0, 30, 60, and
120 min after insulin injection. All animal procedures were approved by
the Washington University Animal Studies Committee.
Glucose uptake by skeletal muscle. Uptake of 2-deoxy-D-[1,2-3H]
glucose (2.25 Ci) by isolated epitrochlearis and extensor digitorum lon-
gus muscle was performed as previously described (22). Briefly, after dis-
section, muscles were allowed to recover for 60 min in flasks containing 2
ml of Krebs-Henseleit bicarbonate buffer (KHB) with 8 mM glucose, 32
mMmannitol, and a gas phase of 95%O2-5%CO2. The flasks were placed
in a shaking incubator maintained at 35°C. After recovery, some muscles
were incubated in the same medium containing 2 mM 5-aminoimida-
zole-4-carboxyamide ribonucleoside (AICAR; Toronto Research Chemi-
cals) or 0.3 M insulin (100 U/ml; Lilly) for 60 min. After treatment, the
muscles were rinsed for 10 min at 29°C in 2 ml of oxygenated KHB con-
taining 40 mM mannitol to remove glucose and treatment agents. After
the rinse step, muscles were incubated for 10 min at 29°C in flasks con-
taining 2 ml of KHB with 1 mM 2-[1,2-3H]deoxyglucose (2-DG; 1.5Ci/
ml) and 36 mM [14C]mannitol (0.2 Ci/ml), with a gas phase of 95%
O2-5% CO2, in a shaking incubator. The muscles were then blotted,
clamp-frozen, and processed for determination of intracellular [3H]2-
DG-6-phosphate accumulation and extracellular space.
Measurement of muscle ATP. ATP and AMP were analyzed by high-
performance liquid chromatography (HPLC) as described previously,
with minor modifications (11). Briefly, muscle tissue was snap-frozen in
liquid nitrogen to preserve metabolites. Nucleotides were extracted from
frozen muscle tissue by sonication in 1 M HClO4 (1 ml/100 mg tissue).
Homogenates were placed on ice for 5 min and centrifuged at 5,000 g
for 10 min. After centrifugation, the supernatant was neutralized with
ice-cold 3 M K2CO3, diluted 1:50 in 10 mM phosphate buffer (pH 7.0),
and analyzed by HPLC with an LC-18T reverse-phase column (Supelco,
Bellefonte, PA) at a flow rate of 1 ml/min. The absorbance at 254 nm was
recorded, and the amount of ATP or AMP was quantified from the chro-
matogram by interpolation from a curve obtained using AMP and ATP
standards (Sigma).
Treadmill test. For analysis of exercise-induced gene expression in
skeletal muscle, 4- to 6-week-old control and 2-deficient animals were
allowed to run for 25 min on a treadmill at 15 m/min. All animals were
returned to their cages after the run.Mice were sacrificed 2 or 6 h after the
run, and skeletal muscles were isolated, flash-frozen in liquid nitrogen,
and stored at 80°C. For the stress test, 2- to 6-month-old WT and 2
knockout (KO) animals were allowed to run on a treadmill at 10 m/min
(time zero). The speed was increased 3 m/min every 3 min. The time was
recorded when they came in contact with the stimulus shock for 7 s (ex-
haustion), at which time the animals were removed from the treadmill.
Magnetic resonance imaging (MRI).Micewere anesthetizedwith 5%
isoflurane in air andmaintained on 1.5% isoflurane in air for the duration
of the experiment. Animals were scanned on a Bruker 7T Biospec system
using a Bruker 72-mm-quadrature coil. Axial and coronal images were
acquired using a spin echo sequence with TR/TE of 400/10.2 ms and 19
slices of 1.25-mm and 1-mm thicknesses, respectively, with in-plane res-
olutions of 0.25 mm by 0.25 mm.
Images were imported into ImageJ (Rasband) and manually seg-
mented three times. The area of each fat segment was measured for each
slice of eachmouse and converted to volumeusing the resolution and slice
thickness. The final estimate was the average of the three individual esti-
mates.
Quantitative RT-PCR analysis. RNA was isolated from skeletal mus-
cle using TRIzol (Invitrogen, San Diego, CA). Quantitative reverse trans-
criptase PCR (RT-PCR) analysis was performed using Sybr green meth-
odology on a model 7500 Fast instrument (Applied Biosystems, Foster
City, CA).
Primer sequences. Primer sequences were as follows: PGC1 (for-
ward), AATCAGACCTGACACAACGC; PGC1 (reverse), GCATTCCT
CAATTTCACCAA; cytochrome c (forward), GGAGGCAAGCATAAGA
CTGG; cytochrome c (reverse), TCCATCAGGGTATCCTCTCC; Cox 4
(forward), AGAAGGAAATGGCTGCAGAA; Cox 4 (reverse), GCTCGG
CTTCCAGTATTGAG; CPT1b (forward), TTGCCCTACAGCTGGCTC
ATTTCC; and CPT1b (reverse), GCACCCAGATGATTGGGATACTGT.
Statistical methods. Student’s t test was used to calculate statistical
significance, with a P of	0.05 representing a statistically significant dif-
ference.
RESULTS
TheAMPK subunits are differentially expressed in tissues.To
examine AMPK  subunit expression patterns, we performed im-
munoblot analysis on tissue lysates from adult wild-type (WT)
mice using an antibody directed against the highly conserved C
termini of the  subunit. This antibody recognizes 1 and 2
subunits, which can be distinguished by their electrophoretic mo-
bilities. These studies showed that 1 and 2 are coexpressed at
relatively equivalent levels in adult brain and heart. However, in
skeletal muscle, 2 was, in essence, the only  subunit present. In
adult liver, pancreas, kidney, and brown fat, 1 was the predom-
inant  subunit expressed (Fig. 1A and B). In the kidney, multiple
1 isoforms were detected (Fig. 1A and E).
AMPK 2 Subunit in Stress Physiology
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To identify specific functions of the 2 subunit, we generated
2-deficient mice. The 2 gene was disrupted using gene trap
technology in ES cells (Bay Genomics), and these ES cells were
used to generate animals harboring the mutant 2 allele. In these
mutant mice, the 2 gene was interrupted after exon 2 by the
insertion of a -Geo cassette (Fig. 1C and D). The 2 mutant
animals grew normally with no overt abnormalities, were fertile,
and lived to old age. Immunoblot analysis confirmed the loss of2
protein in all tissues of these mutant animals (Fig. 1E).
To examine whether the 1 protein in 2-deficient muscle is
complexed with an AMPK subunit, we immunoprecipitated the
1 and 2 subunits and performed immunoblotting using 1/2
C-terminus-specific antibody (Fig. 2A). While AMPK  subunits
were found predominantly in complexes with 2 in WT gastroc-
nemius muscle, /1-containing complexes are clearly present in
2-deficient muscle. While both 1- and 2-containing AMPK
complexes were detected in brain, the liver contained almost ex-
clusively 1-associated complexes, in accord with the extremely
low expression of 2 in this organ.
To monitor the effect of 2 subunit loss on AMPK activity, we
examined AMPK  subunit phosphorylation in tissues from 2
mutant animals using immunoblot analysis. We found that
AMPK subunit phosphorylation was largely similar in all tissues
except skeletal muscle (32.2% of WT), which predominantly ex-
presses 2 (Fig. 2B and C). pAMPK levels were also slightly lower
in 2 mutant kidney. A direct examination of AMPK function
using a SAMS peptide assay also showed decreased activity, con-
sistent with the immunoblot results with the pAMPK antibody
(Fig. 2D).
We further examined the phosphorylation state of selected
AMPK downstream substrates in tissues from 2 mutant mice.
AMPK negatively regulates mTOR by phosphorylating Raptor to
inhibit protein translation and ribosome biogenesis (21, 25). The
modulation of mTOR activity by AMPK is reflected in the al-
tered phosphorylation of the mTOR substrates S6 and 4EBP1.
It also phosphorylates the mammalian autophagy protein Ulk1
to protect cells during nutrient stress (14, 31). In addition,
AMPK phosphorylation of FOXO3 regulates oxidative stress
resistance (20). Although phosphorylation of AMPK sites of
Raptor (Ser792), Ulk1(Ser555), and FOXO3 (Ser413) was clearly
reduced in AMPK2-deficient skeletal and cardiac muscle, to-
tal expression levels of these proteins were comparable between
WT and 2-deficient animals (data not shown). This indicates
that AMPK-dependent phosphorylation of these substrates is
dependent on AMPK2 complexes (Fig. 2B). The liver primar-
ily expresses the 1 subunit, and accordingly, there were no
differences in Raptor or ULK1 phosphorylation between WT
and 2 mutant animals (Fig. 2B). We observed an unexpect-
edly high level of FOXO3 phosphorylation in liver from 2
mutant animals. Collectively, these results demonstrate organ-
specific regulation of AMPK substrate phosphorylation by
AMPK2 complexes and show that 2 mutant skeletal muscle
is deficient in AMPK activity despite the compensatory in-
crease in 1 levels.
AICAR-stimulated glucose uptake is impaired in skeletal
muscle of 2-deficient mice. AMPK regulates glucose metabo-
lism in part by increasing glucose utilization in muscle and inhib-
iting gluconeogenesis in the liver. To assess the impact of 2 sub-
unit loss on glucose metabolism, we measured serum glucose
levels in 2-deficient animals. The plasma glucose level in 2-
mutant animals trended higher but did not reach statistical signif-
icance (Fig. 3A). Next, to evaluate the acute response of these
mutant animals to a glucose challenge, we injected dextrose (2
g/kg). However, no evidence of glucose intolerance was observed,
despite the 70% decrease in muscle AMPK activity (Fig. 3B).
Pharmacological activation of AMPK stimulates glucose up-
take in skeletal muscle via the glucose transporter Glut4 in skeletal
muscle. We utilized isolated muscle preparations to examine
AMPK-mediated increases in glucose uptake in response to the
AMPK activator AICAR. Muscles from WT and 2 mutant mice
were incubated in the presence or absence of AICAR (2 mM) for
60min, and glucose uptake wasmeasured bymonitoring intracel-
lular [3H]2-DG content (13).We found that Glut4 expression and
basal glucose uptake were similar inWT and2-deficientmuscles
(Fig. 3C and D); however, in contrast toWTmuscle, there was no
AICAR-mediated increase in glucose uptake in muscles from 2
mutant animals (Fig. 3D and E).
FIG 2 Loss of AMPK 2 causes extensive loss of AMPK activity in skeletal
muscle. (A) Immunoblot using the 1/2 antibody following immunopre-
cipitation of  subunits with 1/2 antibody. AMPK /1 and/or AMPK /2
complexes were detected in brain, liver, and gastrocnemius muscle. (B) Im-
munoblot analysis of phosphorylated AMPK (pAMPK), pRaptor, pULK1, and
pFOXO3 in organs of 2 mutant mice using phospho-specific antibodies.
-Actin was used as a loading control. (C) Densitometric analysis of pAMPK
in organs of 2 mutant mice. AU, arbitrary units. (D) AMPK activity analysis
from tissue lysates of WT and 2 mutant animals using SAMS peptide as a
substrate. *, P	 0.001.
Dasgupta et al.
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Intraperitoneal injection of AICAR (1 mg/g body weight)
failed to significantly increase pAMPK and pACC levels in 2-
deficient gastrocnemius muscle (Fig. 3F and G). We also exam-
ined the role of AMPK2 complex in AICAR-stimulated phos-
phorylation of selected AMPK substrates in skeletal muscle from
these animals. As shown in Fig. 3F, phosphorylation of Raptor and
Ulk1 was decreased both basally and after AICAR treatment in
2-deficient gastrocnemius muscle, although total protein levels
were unaffected (data not shown). Phosphorylation of the mTOR
target S6 was higher basally but was reduced similarly by AICAR
treatment in WT and 2 mutant muscles. These results indicate
that AMPK2 complexes participate in the AICAR-stimulated
phosphorylation of these canonical AMPK targets in skeletal
muscle.
Active AMPK regulates lipid metabolism in part by inhibiting
cholesterol and fatty acid synthesis in the liver. In 2-deficient
mice, these metabolites were present at normal levels, perhaps
reflecting the relatively normal level of liver AMPK (Fig. 3H to J).
Overall, these results showed that while glucose uptake and me-
tabolism, as well as cholesterol and lipidmetabolism, were similar
in WT and 2 mutant animals under basal conditions, maximal
glucose uptake in response to AICAR-stimulated AMPK activa-
tion was impaired in 2-deficient skeletal muscle.
TheAMPK2 subunit is required formetabolichomeostasis
in response to nutritional stress. In addition to controlling basal
metabolism, AMPK plays a crucial role in maintaining energy
homeostasis during periods ofmetabolic stress. Althoughnoovert
abnormalities were observed in 2-deficient animals under nor-
mal conditions, we suspected that their response to stressful con-
ditionsmight be abnormal. To pursue this idea, we first examined
their response to nutritional deprivation. Two-month-old WT
and 2 mutant animals were fasted for 24 or 48 h. All WT and
mutant animals survived this challenge; however, while monitor-
ing the animals, we noticed that mutant animals moved more
sluggishly thanWTmice after 48 h of fasting.Wemeasured serum
glucose and lipid levels in these animals and found that even after
48 h of fasting, serum cholesterol, free fatty acid, and triglyceride
levels in WT and mutant animals were similar (Fig. 4A to C). In
contrast, plasma glucose levels in fasted mutant animals were
much lower than those in fastedWTmice (Fig. 4D). Insulin levels
FIG 3 AMPK2mutant animals have normal glucose and lipid profiles but impaired AICAR-stimulated glucose uptake. Shown are basal glucose levels (A) and
glucose tolerance tests (B) inWT and2mutantmice (n
 6 to 10 for each group). (C) Immunoblot analysis of total Glut4 inWT and2mutant skeletalmuscle.
(D and E) AICAR-stimulated 2-[3H]deoxyglucose uptake by epitrochlearis and extensor digitorum longus (EDL) muscles isolated from WT and 2 mutant
animals (n 
 6 to 10 for each group). *, P 
 0.0001; **, P 
 0.003. (F) Immunoblot using pAMPK, pACC, pRaptor, pULK, and pS6 antibodies shows
AICAR-stimulated levels of active AMPK and phosphorylation of AMPK downstream targets in gastrocnemius muscle of WT and 2 mutant animals. Total
AMPK, ACC, and S6 are also shown.-Actin was used as a loading control. (G)Densitometry of pAMPK and pACC levels in control and AICAR-stimulatedWT
and 2 mutant gastrocnemius muscle. #, P 0.005. (H to J) Levels of serum cholesterol, triglyceride, and free fatty acid (FFA) in 2 mutant animals (n
 6 to
10 for each group).
AMPK 2 Subunit in Stress Physiology
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also appeared lower in mutant mice, but these reductions did not
reach statistical significance (data not shown). Immunoblot anal-
ysis with pAMPK-specific antibodies was performed to examine
AMPK activation in response to food restriction. While fasting
induced higher levels of pAMPK and pACC in WT mice, no
changes in phosphorylated AMPK or ACC were observed in skel-
etalmuscle from fasted2-deficientmice (Fig. 4E and F).We next
examined the phosphorylation of selected AMPK substrates in
skeletal muscle of fed and fasted animals. In fed 2 mutant ani-
mals, levels of pRaptor (Fig. 4E) but not total raptor (data not
shown) were reduced. The phosphorylation of the mTOR targets
S6 and 4EBP1was increased in fedmutant animals but was down-
regulated by fasting in a fashion similar to that observed in WT
fasted animals (Fig. 4E).
We next measured muscle glycogen content in fed and fasted
2 mutant animals, as muscle glycogen is a prime source of glu-
cose and energy during prolonged fasting. The basal glycogen con-
tent of these mutant mice in the fed state was significantly lower
than that of control animals (Fig. 4G). Furthermore, while fasting
caused 20% reduction in muscle glycogen in WT animals, 2-
deficient mice completely failed to break down muscle glycogen
even after a 48-h fast (Fig. 4G).
We also assessed basal energy content in 2-deficient gastroc-
nemiusmuscle bymeasuring the ATP/AMP ratio. InWT animals,
the ATP/AMP ratio decreased considerably after fasting for 48 h;
however, this ratio was unchanged in fasted 2 mutant mice (Fig.
4H). Collectively, these studies suggest that decreased AMPK ac-
tivation in 2-deficient skeletal muscle results in aberrant glucose
homeostasis, decreased muscle glycogen, and reduced muscle en-
ergy stores.
2-deficient mice demonstrate metabolic syndrome upon
exposure to a high-fat diet.Animals fed a high-fat (Western) diet
(HFD) developmetabolic syndrome, a condition characterized by
hyperglycemia, insulin resistance, and hyperlipidemia. The role of
AMPK in regulating fatty acid metabolism encouraged us to ex-
amine whether 2 mutant animals developed any of these meta-
bolic abnormalities when maintained on an HFD. Wild-type an-
imals weighed 30% more after 12 weeks on an HFD than
animals fed normal chow; in contrast, 2-deficient animals on an
HFD weighed 48% more than their chow-fed counterparts (Fig.
5A). The differences appeared to be more noticeable in males, but
this difference was not significant. We also measured body fat
content (30) and found that 2 mutant mice maintained on an
HFD had a significantly larger amount of fat (4 to 5 times) than
FIG 4 Reduced basal muscle glycogen and fasting hypoglycemia in AMPK 2-deficient mice. Histograms show serum cholesterol (A), free fatty acid (FFA) (B),
and triglyceride (C) levels inWT and2mutant animals (n
 8 per group). (D)Glucose levels in 48-h-fastedWT and2mutant animals (n
 7 for each group).
*, P
 0.002. (E) Immunoblot showing levels of pAMPK, pACC, pRaptor, pULK1, p4EBP1, and pS6 as well as total AMPK, ACC, and S6 in gastrocnemiusmuscle
from WT and 2-deficient mice after fasting. -Actin was used as a loading control. (F) Densitometry of pACC levels in fed and fasted WT and 2 mutant
gastrocnemius muscle. #, P
 0.005. (G) Glycogen content in skeletal muscle from fed and fasted (48 h) WT and 2 mutant animals. *, P
 0.01; $, P
 0.004.
(H) ATP/AMP ratio in skeletal muscle of fed and 48-h-fasted WT and 2 mutant animals. **, P
 0.05.
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comparably fedWT animals (Fig. 5B). Magnetic resonance imag-
ing of WT and 2 mutant animals on HFD revealed a significant
increase in fat mass versus lean mass (Fig. 5C and D) and an
increase in fat volume (Fig. 5E) in2mutant animals compared to
WT animals.
The metabolic syndrome induced by HFD is characterized by
increases in serum triglyceride levels. Serum cholesterol and free
fatty acid levels in 2-deficient and wild-type animals maintained
on an HFD were comparable (data not shown). In contrast, we
found that triglyceride levels in 2-deficient animals on an HFD
were nearly double those found in their WT counterparts (Fig.
5F). We also examined serum glucose levels, and as expected, WT
mice fed an HFD developed hyperglycemia. This HFD-induced
increase in serum glucose was further enhanced in 2 mutant
animals (Fig. 5G). Consistent with these results, glucose tolerance
tests revealed HFD-induced changes that were more severe in 2-
deficient mice (Fig. 5H and I). While basal insulin levels were
normal in 2-deficient mice, these animals manifested an exag-
gerated increase in insulin levels when maintained on an HFD
(Fig. 5J). To investigate whether insulin resistance caused by an
HFD was exacerbated in 2 mutant animals, we performed insu-
lin sensitivity tests on WT and mutant animals maintained on a
normal diet or HFD. All animals maintained on an HFD showed
classical signs of insulin resistance; however, these changes were
clearly more severe in 2 mutant animals (Fig. 5K). These results
indicate that loss of the AMPK 2 subunit disrupts metabolic
homeostasis and results in features associated withmetabolic syn-
drome.
FIG 5 AMPK 2 mutant mice maintained on an HFD develop metabolic syndrome. (A) Body weights of WT and 2 mutant animals after 12 weeks on normal
chow or an HFD (n
 8 for each group). **, P
 0.02; #, P
 0.0003. (B) Fat content (expressed as ratio of 2 mutant toWT) of animals maintained on an HFD
for 12 weeks (n
 8 for each group). *, P	 0.001. (C) Representative MRI images (coronal section) of WT and 2 mutant mice on an HFD. The areas of high
signal intensity are fatty areas. (D and E) Quantitation of fat and lean mass (D) and fat volumes (E) of WT and 2 mutant mice on an HFD. AU, arbitrary units.
(F) Serum triglyceride levels ofWT and 2mutant animals after 12 weeks on anHFD (n
 8 for each group). #, P
 0.0003. (G to I) Basal glucose levels (G) and
glucose tolerance tests (H and I) ofWT and 2mutant animals maintained on the indicated diet (n
 8 for each group). $, P
 0.001; #, P
 0.009; **, P
 0.04;
*, P 0.03. (J and K) Steady-state insulin levels (J) and insulin sensitivity test (K) in WT and 2 mutant animals fed normal chow or an HFD (n
 7 for each
group). **, P
 0.05; #, P
 0.006; $, P
 0.05.
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AMPK plays a crucial role in skeletal muscle glucose uptake,
and animals on an HFD show impaired glucose transport (17).
We sought to determine whether insulin-stimulated glucose up-
take is compromised in 2 mutant animals fed either a normal
diet or an HFD. We measured insulin-stimulated glucose uptake
ex vivo using epitrochlearis and EDLmuscles isolated fromWT or
2 mutant animals maintained on a normal diet or an HFD. We
found that baseline glucose ([3H]-2-DG) uptake in muscles from
mutant animals was lower than that observed in their WT coun-
terparts, although it did not reach statistical significance (Fig. 6A).
Glucose uptake was stimulated by insulin in bothWT andmutant
mice fed normal chow, but this response was less robust in 2-
deficient animals (Fig. 6A). Insulin-stimulated glucose uptakewas
compromised in all mice fed an HFD, with more severe deficits
observed in 2-deficient animals (Fig. 6A). In concert with these
results, AMPKactivity is severely reduced inmuscles of2mutant
mice fed an HFD (92% compared to WT chow-fed animals)
(Fig. 6B). ACC phosphorylation was concomitantly reduced in
muscle from 2 mutant animals on an HFD versus normal chow
(Fig. 6B and C). We also investigated whether the AMPK2 com-
plex is essential for downstream phosphorylation of selected sub-
strates in response to fasting (Fig. 6B).We found little diet-depen-
dent alteration in Raptor phosphorylation and no significant
differences in WT versus 2 mutant animals. We did observe sig-
nificant increases in the levels of pS6 and p4EBP1 in chow-fed 2
mutant animals. The phosphorylation of these proteins was dra-
matically reduced in bothWT andmutant animalsmaintained on
an HFD, suggesting additional AMPK-independent regulation of
their function during metabolic stress.
Since AMPK plays an important role in the translocation of glu-
cose transporters from the intracellular space to the plasma mem-
brane, we reasoned that reduced AMPK activity in muscles of the
mutant animals might lead to reduced insulin-stimulated transloca-
tion of Glut4, the major glucose transporter in skeletal muscle (27).
We prepared total protein lysates and plasma membrane fractions
from epitrochlearis muscles of WT and 2-deficient mice main-
tained on an HFD. Immunoblot analysis showed that total Glut4
levels were not significantly altered in 2 mutant mice fed a normal
diet (Fig. 6D, lower panel); however, membrane-associated Glut4
levelsweremarkedly reduced inmutant animals onanHFD(Fig. 6D,
upper panel). Taken together, our results demonstrate that animals
lacking the AMPK 2 subunit become hypoglycemic during acute
metabolic stress (fasting) and develop features reminiscent of meta-
bolic syndrome whenmaintained on anHFD.
The2 subunit is required for normal exercise performance.
AMPK is a major regulator of skeletal muscle energy metabolism.
It is activated in response to the increased energetic load produced
by exercise. The increased AMPK activity allows the muscle to
adapt to both short-term (by stimulating glucose utilization) and
long-term (by augmenting breakdownof glycogen and fatty acids)
FIG 6 Reduced insulin-stimulated glucose uptake and plasma membrane-associated glucose transporter expression in 2 mutant animals. (A) Baseline and
insulin-stimulated 2-DGuptake in isolated skeletal muscles fromWT and2mutant animals fed normal chow or anHFD. *, P	 0.05. (B) Immunoblot analysis
of epitrochlearis muscle from above animals using antibodies to pAMPK, pACC, pRaptor, pULK1, p4EBP1, pS6, and total S6. -Actin and tubulin were used as
loading controls. (C) Densitometry of pAMPK and pACC levels in epitrochlearis muscle of chow- or HFD-fed WT and 2 mutant mice. (D) Immunoblot
analysis of epitrochlearis muscle from same animals using Glut4 antibodies to show total (t) and membrane-associated (m) Glut4.
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energy demands of the muscle. To test whether a lack of 2 sub-
unit in muscle affected exercise performance, we initially tested
motor coordination and neuromuscular function in 2 mutant
mice.We evaluated these animals using rotarod and sensorimotor
tests andmeasured nerve conduction velocities, but no abnormal-
ities were observed (data not shown). We next monitored the
endurance of age-matched WT and 2 mutant animals using a
treadmill test.We found that regardless of age (i.e., 2 to 6months),
2-deficient mice became exhausted after a much shorter time
than their WT counterparts (Fig. 7A). These results suggest that
improper AMPK activation during exercise compromises the per-
formance of these mutant mice.
ActivationofAMPKandsubsequentAMPK-mediatedchanges in
gene expression are crucial steps in the muscle response to exercise.
To examine whether 2-deficient muscle has a reduced capacity to
upregulate mitochondrial genes, WT and mutant animals (4 to 6
weeks old) were allowed to run on a treadmill set at a constant speed
of15m/min for25min,whichwas themaximal time2mutantmice
could run at this speed. Quantitative RT-PCR analysis of gas-
trocnemius muscle harvested 6 h postexercise revealed that
exercise-induced PGC1 and PGC1 target gene expression
(e.g., cytochrome c, Cox4, and CPT1b) were significantly reduced
in 2-deficient muscle (Fig. 7B). Moreover, while AMPK was ac-
tivated with concomitant phosphorylation of ACC after exercise
(2 h) in gastrocnemius muscle of WT animals, no significant ex-
ercise-induced increase in pAMPK or pACC levels was observed
in 2-deficient muscle (Fig. 7C).
We further investigated the phosphorylation of AMPK sub-
strates in skeletal muscle from 2 mutant animals after exercise
(treadmill run). Raptor phosphorylation was increased after exer-
cise in WT muscle but not in 2 mutant muscle (Fig. 7C), al-
though total raptor levels remained unchanged (data not shown).
Accordingly, mTOR signaling in 2-deficient muscle was en-
hanced after exercise, as evidenced by the robust increase in pS6
and p4EBP1 compared to levels in WT muscle (Fig. 7C).
Muscle glycogen is the primary carbohydrate fuel formuscular
work during strenuous exercise. To understand why 2 mutant
animals have a reduced exercise capacity, we compared basal and
postexercise levels of muscle glycogen. The baseline muscle glyco-
gen content of mutant animals was38% lower than in WT an-
imals. While glycogen content in the 2-h-postexerciseWTmuscle
was reduced by 23%, no change in muscle glycogen was ob-
served in the 2 mutant mice following exercise (25 min on the
treadmill) (Fig. 7D). We also measured the ATP/AMP ratio im-
mediately after exercise and 2 h postexercise and found that the
low ratio present in 2-deficient muscle at baseline was further
FIG 7 Poor exercise endurance in 2 mutant animals. (A) Performance of WT and 2 mutant animals in the treadmill running assay (n
 7 for each group).
**, P	 0.0001. (B) Quantitative RT-PCR analysis of gastrocnemiusmuscle fromWT and2mutantmice 6 h after and before the treadmill run. For each group,
datawere normalized to-actin expression. *,P	 0.05. (C) Immunoblot analysis of pAMPK, pACC, pRaptor, pULK1, pFOXO3, p4EBP1, pS6, total S6, and total
4EBP1 in gastrocnemiusmuscle fromWTand2mutantmice showing basal and exercise-induced levels of AMPKactivation.Note that total AMPKbut not total
ACC levels were reduced in 2 mutant animals. -Actin and tubulin were used as loading controls. (D to F) Glycogen content at baseline and 2 h postrun (D)
and ATP/AMP ratio at baseline and immediately after run (E) and 2 h postrun (F) in the epitrochlearis muscle ofWT and 2mutant animals. *, P	 0.03; #, P	
0.01.
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decreased after exercise (Fig. 7E and F), indicating the inability to
maintain metabolic homeostasis in the absence of normal AMPK
activity.
Collectively, our results indicate that the AMPK 2 subunit is
important for exercise-induced AMPK activation, AMPK-depen-
dent gene expression, and energy production in addition to its role
in muscle glycogenolysis and optimal exercise performance.
DISCUSSION
We dissected the biological roles of the regulatory 2 subunit of
AMPK through the analysis of2-deficientmice.Unlike thewide-
spread expression of the closely related 1 subunit, 2 expression
is restricted primarily to brain, heart, kidney, and skeletal muscle,
with the last tissue expressing almost exclusively the 2 subunit.
Consistent with its unique muscle expression, we found that 2 is
required for stress-induced AMPK-regulated functions in skeletal
muscle. While we were finishing our studies on the 2 mutant
animal, another group reported the generation of another strain
of 2-deficient mice and muscle-specific 1/2-deficient mice
(41, 47). While their results are largely consistent with ours, key
mechanistic studies in this report determinewhether or not the2
subunit is required for organ-specific baseline phosphorylation of
a number of AMPK substrates and whether it is required in skel-
etal muscle during physiological and pharmacological AMPK ac-
tivation. Our results also unveil specific roles of 2 subunit in
response to nutrient deprivation and exercise-induced stress ad-
aptation.
The 2mutant mice we generated are overtly normal despite a
complete loss of the 2 subunit in all tissues. Adult brain and
cardiac muscle express the two  subunits at similar levels, and
pAMPK levels were similar in these two tissues in WT and 2
mutant animals. This suggests that the 1 subunit can maintain
active AMPK in 2-deficient cardiac muscle and brain at levels
similar to those in WT animals. However, the absence of the 2
subunit reduced basal phosphorylation of Raptor, ULK1, and
FOXO3 in heart but not in brain. These results suggest that 2-
dependent AMPK complex is specifically required to phosphory-
late this subset of AMPK substrates in the cardiac muscle but not
in the brain. Future studies in various organs will reveal the organ
and context-specific function of the two  subunits in regulating
AMPK substrate phosphorylation.
InWT skeletal muscle, we found extremely low levels of the1
subunit, and consequently, only catalytic  subunits associated
with the 2 subunit were detected. These results are in contrast to
the study by Steinberg et al. (47), in which 1 was found to be
predominantly associated with the  catalytic subunit. The rela-
tive tissue expression of the two  subunits in wild-type animals
was not reported, thus making it difficult to interpret these asso-
ciation results. Despite these discrepancies, the two studies to-
gether present a persuasive case for the importance of the 2 sub-
unit in regulating AMPK function in response to stress.
The2mutant animals showed essentially normal glucoseme-
tabolism, similar to AMPK1-deficientmice (27), suggesting that
the upregulation of the 1 subunit detected in 2-deficient skel-
etalmuscle enables the formation of functional AMPKcomplexes.
In contrast to the basal condition, AICAR-stimulated AMPK
phosphorylation and glucose uptake were completely blunted in
2mutantmuscle, suggesting that2-dependent AMPK function
is essential for maximal but not basal glucose import. This pheno-
type is reminiscent of that in animals lacking the AMPK 3 sub-
unit (2). Our results, together with these previous studies, indicate
thatAMPKcomplexes composed of2 (27),2, and3 (2) are the
predominant source of AMPK activity in muscle. Targeting such
complexes with small molecules may provide a relatively specific
approach to modulating AMPK activity in skeletal muscle.
The loss of2 did not cause abnormalities in lipidmetabolism,
presumably reflecting the normal AMPK function in liver, pan-
creas, and adipose tissue that is mediated by the predominant 1
subunit in these tissues. A unique finding of our study is the re-
quirement for the 2 subunit in adaptive responses to starvation.
In skeletal muscle, AMPK is activated in fasted WT animals with
corresponding phosphorylation of ACC but not Raptor and
ULK1. While pS6 and p4EBP levels are higher in 2 mutant mus-
cle, fasting induces a dramatic reduction in levels of these phos-
phorylated proteins, indicating that the remaining AMPK1
complexes are sufficient to respond to fasting or thatmTOR is also
regulated by AMPK-independent mechanisms after fasting. Fast-
ing represents an acute metabolic stress that induces hormonal
and cytokine responses to ensure energy homeostasis and main-
tenance of euglycemia. Thus, hypoglycemia in fasted 2 mutant
animalswas unexpected becausemetabolic adaptation to fasting is
an important function of the liver, a tissue with very low levels of
2 expression. Glucagon, catecholamines, and ketone bodies also
play crucial roles in the metabolic adaptations to fasting; thus,
further studies are needed to test whether 2 regulates the pro-
duction or responses to these molecules or, perhaps, adaptive re-
sponses that emanate from the central nervous system.
Skeletal muscle plays a pivotal role in glucose homeostasis.
Impaired muscle glucose metabolism induced by the high-fat
Western diet is frequently associated with metabolic syndrome.
Although the mechanism is not clearly understood and there is
some controversy about the extent of its role, AMPK in general
opposes the deleterious effects of metabolic syndrome (17, 29, 51,
52). While Fujii et al. (17) observed insulin resistance in FVB
animals expressing muscle-specific kinase-dead AMPK2, Jør-
gensen et al. (29) did not observe such a phenotype in theC57/BL6
background. Consistent with others (41, 47), our study shows that
AMPK complexes in muscle contain primarily the 2 subunit,
and2mutant animalsmaintained on anHFDhave high body fat
(compared to wild-type animals on an HFD) and manifest fea-
tures of metabolic syndrome.
Muscle AMPK signaling has been shown to be impaired by
obesity (35). Consistent with this result, we found that muscles of
wild-type mice fed an HFD had reduced pAMPK levels. pAMPK
levels were further reduced in 2 mutant animals, suggesting that
2 is an important regulator of muscle AMPK activity during
metabolic stress induced by an HFD. Despite reduced pAMPK
and pRaptor levels in skeletal muscle from animals maintained on
anHFD, S6 and 4EBP1 phosphorylationwas significantly reduced
in both WT and 2 mutant skeletal muscle, indicating AMPK-
independent mTOR regulation in this tissue in response to an
HFD. Unlike muscle from WT animals on HFD, Raptor phos-
phorylation in 2-deficient muscle from animals on an HFD was
not reduced compared to that inmuscles from animals on normal
chow. This again points to a complex regulation of the AMPK
mTOR axis in mice exposed to a Western diet.
One manner in which glucose metabolism is increased by
AMPK is through increasing translocation of glucose transporters
to the cell surface (36, 39, 43, 55). Consistent with the study of
Steinberg et al. (47), total Glut4 levels were equivalent in muscle
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from2mutantmice andwild-typemicemaintained on a normal
diet. However, in 2 mutant animals on an HFD, we found that
surface Glut4 levels decreased significantly, suggesting that Glut4
translocation is regulated by AMPK complexes containing 2.
Another mechanism by which an HFD alters glucose metabolism
is via inhibition of glucose phosphorylation (18); however, a role
for 2 in regulating this process has not been investigated.
Increases in aerobic metabolism, insulin resistance, and obesity
are all induced by anHFDand are risk factors for the development of
metabolic syndrome in humans (8). The loss of AMPK activity in
skeletalmuscles of2-deficientmice also leads to abnormalities rem-
iniscentofmetabolic syndrome. Inaccordwith thesefindings,AMPK
activating agents can reversemetabolic syndrome ingenetically obese
rodents and are also effective in treating diabetic patients with re-
duced insulin sensitivity (16, 23). Results obtained in studies of 2
mutantmice strongly support a role for thisAMPKsubunit in abnor-
malities associated with metabolic syndrome and suggest that drugs
that activate AMPK complexes containing the 2 subunit could be
used to treat diabetes and obesity.
During fasting, skeletal muscle glycogen is broken down to
glucose to provide a valuable source of energy (2, 6, 12, 32). AMPK
activation in skeletal muscle during fasting also promotes energy
conservation through the inhibition of biosynthetic processes
(11). The failure of2mutant animals tomaintain energy balance
during fasting indicates the role of this AMPK subunit in this
adaptive response, which includes hepatic gluconeogenesis, fatty
acid oxidation, and glycogen breakdown in liver and skeletalmus-
cle. The reduced glycogen levels we and others (47) observed in
skeletal muscles of 2-deficient animals have also been reported
for AMPK 2 and 3 mutant animals (2, 51). Multiple mecha-
nisms regulate glycogen synthesis and breakdown that could ac-
count for this deficiency (4). For example, glycogen synthesis is
regulated by insulin-mediated Akt activation through its inhibi-
tion of GSK3 (34), a pathway that may also be influenced by
AMPK. Alternatively, 2-dependent AMPK activity might be re-
quired for muscle glycogen accumulation through the allosteric
activation of glycogen synthase caused by increased glucose-6-
phosphate (24). In addition to the low basal glycogen levels, our
results suggest a crucial role for 2-dependent AMPK activity in
fasting-induced glycogenolysis. It is worth noting in this regard
that both AICAR and AMP enhance glycogen phosphorylase ac-
tivity and glycogenolysis in rat skeletal muscle (56).
An important finding of our study is that mice lacking 2,
which constitutes90% of the total  subunit in skeletal muscle,
demonstrated poor exercise performance. The skeletal muscle in
these mutant mice also has lower basal energy content, as basal
glycogen levels are reduced. In addition, whileWTmuscle showed
23% reduced glycogen content after 2 h of exercise, glycogen levels
did not change in 2 mutant animals. This is likely due to failure
of glycogen breakdown in response to exercise, suggesting that
AMPKcomplexes containing2 enhance glycogen phosphorylase
activity (56). Alternatively, reduced AMPK activity could increase
glycogen synthase (GS) activity specifically in the postexercise
muscle (thus increasing postexercise glycogen resynthesis). This is
consistent with studies showing that AMPK2 inhibits glycogen
synthase in renal tubules (5) and muscle (15).
In contrast to nutrient stress (fasting and HFD), we found a
direct negative relationship between AMPK and mTOR signaling
during exercise. AMPK was activated in muscle in animals that
were exercised, and this kept mTOR signaling at low levels (no
significant increase in pS6 and p4EBP1) in WT muscle. In sharp
contrast, levels of phosphorylated S6 and 4EBP1 increased inmus-
cle from 2-deficient animals after exercise, suggesting that
AMPK2 complexes are essential for reducing mTOR signaling
during exercise. Importantly, we also found that 2 is necessary
for exercise-induced AMPK activity and for increased transcrip-
tion of PGC1 and PGC1 target genes. In contrast, 2-deficient
skeletal muscle shows decreased PGC1 basal transcriptional ac-
tivity but normal exercise-induced activity, suggesting that com-
pensation from the remaining 1 subunit promotes exercise-
induced AMPK activation (28). In the study by Steinberg et al.
(47), there was a trend toward reduced expression of PGC1 and
Cpt1b in 2-deficient muscle after exercise. Our study shows that
expression of PGC1 and other mitochondrial genes is signifi-
cantly reduced in gastrocnemius muscle 6 h postexercise. While
themuscle source and time of collectionwere not reported in their
study (47), it should be noted that gene expression can vary sig-
nificantly with time and muscle type after physical exercise. This
could account for some of the discrepancies observed between
these studies.
Although it is clear that exercise induces activation and nuclear
translocation of AMPK (38, 40), and decreased AMPK activity
reduces voluntary exercise (51), questions remain with regard to
the role of AMPK during muscle contraction (27, 28). AMPK
activation in skeletal muscle during exercise improves athletic
performance (28), and mice treated with AMPK activating com-
pounds exhibit superendurance (26, 40). The current results pro-
vide compelling evidence that AMPK complexes containing 2
are crucial for muscle contraction during exercise performance,
and they provide an opportunity to explore the therapeutic value
of agents that target 2-containing AMPK complexes to promote
AMPK activity specifically in muscle.
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